Idiopathic Pulmonary Fibrosis Global Market Report 2025

Idiopathic Pulmonary Fibrosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on idiopathic pulmonary fibrosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.
Description:

Where is the largest and fastest growing market for idiopathic pulmonary fibrosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The idiopathic pulmonary fibrosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope

Markets Covered:1) By Drug Type: Nintedanib; Pirfenidone; Other Drug Types

2) By Mode Of Action: Antifibrotic Agents; Tyrosine Kinase Inhibitors; Other Modes Of Action

3) By Route Of Administration: Oral; Parenteral

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Providers

5) By End Users: Hospitals And Clinics; Other End Users

Subsegments:

1) By Nintedanib: Indications; Dosage Forms; Administration Routes

2) By Pirfenidone: Indications; Dosage Forms; Administration Routes

3) By Other Drug Types: Specific Agents Or Classes; Emerging Therapies; Combination Therapies

Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG; Bristol-Myers Squibb Company; AstraZeneca PLC

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.


1. Executive Summary
2. Idiopathic Pulmonary Fibrosis Market Characteristics
3. Idiopathic Pulmonary Fibrosis Market Trends And Strategies
4. Idiopathic Pulmonary Fibrosis Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market
5. Global Idiopathic Pulmonary Fibrosis Growth Analysis And Strategic Analysis Framework
5.1. Global Idiopathic Pulmonary Fibrosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Idiopathic Pulmonary Fibrosis Market Growth Rate Analysis
5.4. Global Idiopathic Pulmonary Fibrosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Idiopathic Pulmonary Fibrosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Idiopathic Pulmonary Fibrosis Total Addressable Market (TAM)
6. Idiopathic Pulmonary Fibrosis Market Segmentation
6.1. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Nintedanib
Pirfenidone
Other Drug Types
6.2. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antifibrotic Agents
Tyrosine Kinase Inhibitors
Other Modes Of Action
6.3. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
6.4. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Providers
6.5. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Other End Users
6.6. Global Idiopathic Pulmonary Fibrosis Market, Sub-Segmentation Of Nintedanib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Indications
Dosage Forms
Administration Routes
6.7. Global Idiopathic Pulmonary Fibrosis Market, Sub-Segmentation Of Pirfenidone, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Indications
Dosage Forms
Administration Routes
6.8. Global Idiopathic Pulmonary Fibrosis Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Specific Agents Or Classes
Emerging Therapies
Combination Therapies
7. Idiopathic Pulmonary Fibrosis Market Regional And Country Analysis
7.1. Global Idiopathic Pulmonary Fibrosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Idiopathic Pulmonary Fibrosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Idiopathic Pulmonary Fibrosis Market
8.1. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Idiopathic Pulmonary Fibrosis Market
9.1. China Idiopathic Pulmonary Fibrosis Market Overview
9.2. China Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Idiopathic Pulmonary Fibrosis Market
10.1. India Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Idiopathic Pulmonary Fibrosis Market
11.1. Japan Idiopathic Pulmonary Fibrosis Market Overview
11.2. Japan Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Idiopathic Pulmonary Fibrosis Market
12.1. Australia Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Idiopathic Pulmonary Fibrosis Market
13.1. Indonesia Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Idiopathic Pulmonary Fibrosis Market
14.1. South Korea Idiopathic Pulmonary Fibrosis Market Overview
14.2. South Korea Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Idiopathic Pulmonary Fibrosis Market
15.1. Western Europe Idiopathic Pulmonary Fibrosis Market Overview
15.2. Western Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Idiopathic Pulmonary Fibrosis Market
16.1. UK Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Idiopathic Pulmonary Fibrosis Market
17.1. Germany Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Idiopathic Pulmonary Fibrosis Market
18.1. France Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Idiopathic Pulmonary Fibrosis Market
19.1. Italy Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Idiopathic Pulmonary Fibrosis Market
20.1. Spain Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Idiopathic Pulmonary Fibrosis Market
21.1. Eastern Europe Idiopathic Pulmonary Fibrosis Market Overview
21.2. Eastern Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Idiopathic Pulmonary Fibrosis Market
22.1. Russia Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Idiopathic Pulmonary Fibrosis Market
23.1. North America Idiopathic Pulmonary Fibrosis Market Overview
23.2. North America Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Idiopathic Pulmonary Fibrosis Market
24.1. USA Idiopathic Pulmonary Fibrosis Market Overview
24.2. USA Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Idiopathic Pulmonary Fibrosis Market
25.1. Canada Idiopathic Pulmonary Fibrosis Market Overview
25.2. Canada Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Idiopathic Pulmonary Fibrosis Market
26.1. South America Idiopathic Pulmonary Fibrosis Market Overview
26.2. South America Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Idiopathic Pulmonary Fibrosis Market
27.1. Brazil Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Idiopathic Pulmonary Fibrosis Market
28.1. Middle East Idiopathic Pulmonary Fibrosis Market Overview
28.2. Middle East Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Idiopathic Pulmonary Fibrosis Market
29.1. Africa Idiopathic Pulmonary Fibrosis Market Overview
29.2. Africa Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Idiopathic Pulmonary Fibrosis Market Competitive Landscape And Company Profiles
30.1. Idiopathic Pulmonary Fibrosis Market Competitive Landscape
30.2. Idiopathic Pulmonary Fibrosis Market Company Profiles
30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
31. Idiopathic Pulmonary Fibrosis Market Other Major And Innovative Companies
31.1. Sanofi S.A.
31.2. Gilead Sciences Inc.
31.3. Toray Industries Inc.
31.4. Boehringer Ingelheim International GmbH
31.5. Viatris Inc.
31.6. Sun Pharmaceutical Industries Limited
31.7. Shionogi and Co. Ltd.
31.8. Cipla Inc.
31.9. Zydus Lifesciences Ltd.
31.10. Chong Kun Dang Pharmaceutical Corp.
31.11. Kyorin Pharmaceutical Co. Ltd.
31.12. Galapagos NV
31.13. Veracyte Inc.
31.14. Genentech Inc.
31.15. FibroGen Inc.
32. Global Idiopathic Pulmonary Fibrosis Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Idiopathic Pulmonary Fibrosis Market
34. Recent Developments In The Idiopathic Pulmonary Fibrosis Market
35. Idiopathic Pulmonary Fibrosis Market High Potential Countries, Segments and Strategies
35.1 Idiopathic Pulmonary Fibrosis Market In 2029 - Countries Offering Most New Opportunities
35.2 Idiopathic Pulmonary Fibrosis Market In 2029 - Segments Offering Most New Opportunities
35.3 Idiopathic Pulmonary Fibrosis Market In 2029 - Growth Strategies
35.3.1 Market Trend Based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings